If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
In November 1949, Pauling, Harvey Itano, S. J. Singer and Ibert Wells published "Sickle Cell Anemia, a Molecular Disease" in the journal Science. It was the first proof of a human disease being caused by an abnormal protein, and sickle cell anemia became the first disease understood at the molecular level. (It was not, however, the first demonstration that variant forms of hemoglobin could be distinguished by electrophoresis, which had been shown several years earlier by Maud Menten and collaborators). Using electrophoresis, they demonstrated that individuals with sickle cell disease have a modified form of hemoglobin in their red blood cells, and that individuals with sickle cell trait have both the normal and abnormal forms of hemoglobin. This was the first demonstration causally linking an abnormal protein to a disease, and also the first demonstration that Mendelian inheritance determines the specific physical properties of proteins, not simply their presence or absence – the dawn of molecular genetics. His success with sickle cell anemia led Pauling to speculate that a number of other diseases, including mental illnesses such as schizophrenia, might result from flawed genetics. As chairman of the Division of Chemistry and Chemical Engineering and director of the Gates and Crellin Chemical Laboratories, he encouraged the hiring of researchers with a chemical-biomedical approach to mental illness, a direction not always popular with established Caltech chemists. In 1951, Pauling gave a lecture entitled "Molecular Medicine".
Dunkin' Donuts LLC, doing business as Dunkin', is an American multinational fast food restaurant chain specializing in coffee and doughnuts. It was founded by Bill Rosenberg in Quincy, Massachusetts, in 1950. The chain was acquired by Baskin-Robbins' holding company Allied Lyons in 1990. Its acquisition of the Mister Donut chain and the conversion of that chain to Dunkin' Donuts facilitated the brand's growth in North America the same year. Dunkin' and Baskin-Robbins eventually became subsidiaries of Dunkin' Brands, headquartered in Canton, Massachusetts, in 2004. Dunkin' Brands was purchased by Inspire Brands on December 15, 2020. The chain began rebranding as a "beverage-led company", and was renamed Dunkin' in January 2019. While stores in the U.S. began using the new name, the company intends to roll out the rebranding to all of its international locations. With approximately 14,200 locations in 39 countries and $14.5 billion in system sales, Dunkin' is one of the largest coffee shop and doughnut shop chains in the world. In addition to several varieties of coffee and doughnuts, products sold include bagels, breakfast sandwiches, muffins, and doughnut holes branded as Munchkins.
Neighbouring countries were aware of the high levels of pollution in the Soviet Union but after the dissolution of the Soviet Union it was discovered that its environmental problems were greater than what the Soviet authorities admitted. The Soviet Union was the world's second-largest producer of harmful emissions. In 1988, total emissions in the Soviet Union were about 79% of those in the United States. But since the Soviet GNP was only 54% of that of the United States, this means that the Soviet Union generated 1.5 times more pollution than the United States per unit of GNP. The Chernobyl disaster in the Ukrainian SSR in 1986 was the first major accident at a civilian nuclear power plant. Unparalleled in the world, it resulted in a large number of radioactive isotopes being released into the atmosphere. Radioactive doses were scattered relatively far. Although long-term effects of the accident were unknown, 4,000 new cases of thyroid cancer which resulted from the accident's contamination were reported at the time of the accident, but this led to a relatively low number of deaths (WHO data, 2005). The disaster contributed to the socio-economic crises that resulted in the collapse of the Soviet Union. Another major radioactive accident that took place in the USSR was the Kyshtym disaster. The Kola Peninsula was one of the places with major problems. Around the industrial cities of Monchegorsk and Norilsk, where nickel, for example, is mined, all forests have been destroyed by contamination, while the northern and other parts of Russia have been affected by emissions.
Sources: en.wikipedia.org
=== Foreign policy === Polls conducted in the late 2010s and early 2020s of adults under the age of 30 show that the top foreign-policy issues for this cohort were combating climate change, preventing the proliferation of weapons of mass destruction, and defending the United States from terrorism. Maintaining American military strength and defending American allies were not as important to young voters. Moreover, young Americans are markedly less concerned about combating America's geopolitical adversaries, notably China and Russia, compared to older voters, who still have lingering sentiments from the (previous) Cold War. A 2019 poll by the International Federation of Accountants found that in the United States, 52% of Generation Z wanted their government to focus more on national problems, a 24% margin ahead of those who thought otherwise. Similarly, 2020 poll conducted by the Center for American Progress found that only 18% of Americans supported liberal internationalism, which has been part of American foreign policy since the time of President Franklin D. Roosevelt, while young Americans were even less likely to support it, contributing to a return towards isolationism, a historical norm dating back to the Founding Fathers. Polls indicates that by 2025, there is broad support for isolationism and tariffs (imposed by President Donald Trump in his trade wars) among Gen-Z Americans.
=== Data validation === Data validation is the application of validation rules to the data. For electronic CRFs the validation rules may be applied in real time at the point of entry. Offline validation may still be required (e.g. for cross checks between data types)
==== Monte Carlo and simulated annealing ==== Monte Carlo is one of the most widely used algorithms for protein design. In its simplest form, a Monte Carlo algorithm selects a residue at random, and in that residue a randomly chosen rotamer (of any amino acid) is evaluated. The new energy of the protein, Enew is compared against the old energy Eold and the new rotamer is accepted with a probability of:
Sources: en.wikipedia.org
Collagen alpha-5(VI) chain also known as von Willebrand factor A domain-containing protein 4 is a protein that in humans is encoded by the COL6A5 gene. COL6A5 is a part of the Collagen VI gene family which produce collagen components for the Extracellular matrix of most connective tissues. In the human genome, part of the collagen VI family is located on chromosome 3q in order of COL6A4, COL6A5, COL6A6. Transcription of COL6A5 only occurs in skin, lung, testis, colon, and small intestine cells.
Radon-222 is generated in the uranium series from the alpha decay of radium-226, which has a half-life of 1600 years. Radon-222 itself alpha decays to polonium-218 with a half-life of 3.8215 days; it is the most stable isotope of radon. Its final decay product is stable lead-206. In theory, 222Rn is capable of double beta decay to 222Ra, and depending on the mass difference between the two, single beta decay to 222Fr may also be allowed. These decay modes have been searched for, yielding lower partial half-life limits of 8 years for both transitions. The latest edition of the Atomic Mass Evaluation gives a mass difference of (−6 ± 8) keV; thus the single beta decay is, probably, forbidden energetically.
In 2005, the US began imposing sanctions targeting Iran's nuclear program, and in 2006 the United Nations Security Council (UNSC) imposed a series of sanctions against Iran. The US and Israel conducted a campaign of cyberwarfare against Iranian nuclear facilities to disrupt their operations, while Israel assassinated several top Iranian nuclear scientists. The UNSC concerns about Iran's nuclear program from 2006 led to the multilateral Joint Comprehensive Plan of Action (JCPOA) between Iran and the P5+1 and the EU in 2015. In January 2020, US president Donald Trump ordered the assassination of Qasem Soleimani, the commander of the Iranian Quds Force. Following the October 7 attacks on Israel and the start of the Gaza war, tensions further escalated with Israel fighting Iran-backed militias across the Middle East, including Hamas, Hezbollah, and the Houthis. Israeli strikes on the Iranian consulate in Damascus and the assassinations of Ismail Haniyeh and Hassan Nasrallah in 2024 were met with Iranian strikes on Israel in April and October. In June 2025, Israel launched the Twelve-Day War by attacking Iranian military and nuclear facilities, provoking Iranian counter-strikes. The United States also joined in support by striking Iranian nuclear facilities during the Twelve-Day War, which ended in a ceasefire. In early 2026, Israeli prime minister Benjamin Netanyahu lobbied President Donald Trump for a joint military strike on Iran, specifically targeting its leadership.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.